ArticleMolecular cancer therapeutics2019
Prospective Clinical Sequencing of Adult Glioma.
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.The Cochrane database of systematic reviews · 2022Pooled it
- Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric malignancies.JCI insight · 2025Article
- Glioma-neuron interactions: insights from neural plasticity.Frontiers in oncology · 2025Review
- Prognostic signature detects homologous recombination deficient in glioblastoma.Translational cancer research · 2024Article
- Clinical sequencing reveals diagnostic, therapeutic, and prognostic biomarkers for adult-type diffuse gliomas.Heliyon · 2024Article
- TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis.Frontiers in immunology · 2024Article
- Article
- A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.The Lancet. Oncology · 2023Review
- Novel immune checkpoint-related gene model to predict prognosis and treatment responsiveness in low-grade gliomas.Heliyon · 2023Article
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.Oncology letters · 2023Article
- Genomic disparities between cancers in adolescent and young adults and in older adults.Nature communications · 2022Article
- Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations.Cancer biology & medicine · 2022Review
- Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2021Review
- Association ofCells · 2021Article
- The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.Acta neuropathologica communications · 2020Article
- EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.BMC cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant gliomas are a group of intracranial cancers associated with disproportionately high mortality and morbidity. Here, we report ultradeep targeted sequencing of a prospective cohort of 237 tumors from 234 patients consisting of both glioblastoma (GBM) and lower-grade glioma (LGG) using our customized gene panels. We identified 2,485 somatic mutations, including single-nucleotide substitutions and small indels, using a validated in-house protocol. Sixty-one percent of the mutations were contributed by 12 hypermutators. The hypermutators were enriched for recurrent tumors and had comparable outcome, and most were associated with temozolomide exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.